References

• 2010Refinement of a viral transmission risk model for blood donations in seroconversion window phase screened by nucleic acid testing in different pool sizes and repeat test algorithms131 cited
• 2005Trends in risk of transfusion-transmitted viral infections (HIV, HCV, HBV) in France between 1992 and 2003 and impact of nucleic acid testing (NAT)96 cited
• 2011Human immunodeficiency virus prevalence, incidence, and residual risk of transmission by transfusions at Retrovirus Epidemiology Donor Study‐II blood centers in Brazil64 cited
• 2018Assessment of HIV transfusion transmission risk in South Africa: a 10‐year analysis following implementation of individual donation nucleic acid amplification technology testing and donor demographics eligibility changes55 cited
• 2013Prevalence of human immunodeficiency virus RNA and antibody in first‐time, lapsed, and repeat blood donations across five international regions and relative efficacy of alternative screening scenarios50 cited
• 2017Residual risk of HIV, HCV and HBV in Canada45 cited
• 2018Prevalence, incidence and residual risk of transfusion-transmitted hepatitis C virus and human immunodeficiency virus after the implementation of nucleic acid testing in Italy: a 7-year (2009-2015) survey.39 cited
• 2017Residual risk of transmission of human immunodeficiency virus and hepatitis C virus infections by blood transfusion in northern Brazil25 cited
• 2014Estimating the residual risk for HIV , HCV and HBV in different types of platelet concentrates in Germany20 cited
• 2018The Brazilian experience of nucleic acid testing to detect human immunodeficiency virus, hepatitis C virus, and hepatitis B virus infections in blood donors17 cited
• 2012Relationship between social capital and test seeking among blood donors in Brazil